Literature DB >> 10194356

Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.

X Wang1, X Zhou, S M Hecht.   

Abstract

Recent findings concerning the structure of the covalent binary complex formed by DNA topisomerase I and its DNA substrate, as well as the nature of interactions with inhibitors that bind reversibly to this binary complex, have led to two proposed models for the binding of the prototype inhibitor camptothecin to the DNA-topisomerase I binary complex. While these models differ in many regards, they both suggest the involvement of the 20-OH group of camptothecin in a donor hydrogen bond with an enzyme side chain functional group. Presently, five analogues of camptothecin that differ only at C-20 have been evaluated for their ability to bind to the topoisomerase I-DNA binary complex and thereby inhibit enzyme function. Both 20-chloro- and 20-bromocamptothecin bound as well to the enzyme-DNA binary complex as 20-aminoCPT despite the absence of a substituent at C-20 capable of contributing a donor hydrogen bond.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194356     DOI: 10.1021/bi982708k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

2.  A theoretical study of some new analogues of the anti-cancer drug camptothecin.

Authors:  Nihar R Jena; Phool C Mishra
Journal:  J Mol Model       Date:  2006-10-06       Impact factor: 1.810

3.  Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2006-10-28       Impact factor: 1.810

4.  A novel preparation method for camptothecin (CPT) loaded folic acid conjugated dextran tumor-targeted nanoparticles.

Authors:  Yuangang Zu; Dan Wang; Xiuhua Zhao; Ru Jiang; Qi Zhang; Dongmei Zhao; Yong Li; Baishi Zu; Zhiqiang Sun
Journal:  Int J Mol Sci       Date:  2011-06-28       Impact factor: 5.923

5.  Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.

Authors:  Gary S Laco
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

6.  Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.

Authors:  Fung-Ming Siu; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2013-09-09       Impact factor: 16.971

7.  Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.

Authors:  Ye Bi; Robert J Lee; Xinyu Wang; Yating Sun; Mengqiao Wang; Lianlian Li; Chenliang Li; Jing Xie; Lesheng Teng
Journal:  Int J Nanomedicine       Date:  2018-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.